Lionco Pharm Grp Co Ltd Net Asset Quality Index
Lionco Pharm Grp Co Ltd net asset quality index. Lionco Pharm Grp Co Ltd (603669) has a Net Asset Quality Index of 57.1% as of June 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥1.12 Billion minus total liabilities of CN¥482.64 Million yields net assets of CN¥641.40 Million. A higher index indicates a stronger, lower-leverage balance sheet. See net assets of Lionco Pharm Grp Co Ltd for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Lionco Pharm Grp Co Ltd (2011–2025)
Net asset quality index of Lionco Pharm Grp Co Ltd from 2011 to 2025. This chart shows how Lionco Pharm Grp Co Ltd's Net Asset Quality Index has evolved across 15 annual periods from 2011 to 2025. As of June 2026, the index stands at 57.1%, representing net assets of CN¥641.40 Million against total assets of CN¥1.12 Billion CNY. Check strategic asset allocation of Lionco Pharm Grp Co Ltd to assess the company's strategic physical and investment asset allocation.
Lionco Pharm Grp Co Ltd Net Asset Quality Index by Year (2011–2025)
Lionco Pharm Grp Co Ltd net asset quality index by year from 2011 to 2025. The table below presents the year-by-year Net Asset Quality Index for Lionco Pharm Grp Co Ltd from 2011 to 2025, covering 15 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see 603669 market cap overview.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 56.0% | CN¥620.28 Million | CN¥1.11 Billion | CN¥486.50 Million | ▼ -5.3 pp |
| 2024 | 61.3% | CN¥769.76 Million | CN¥1.26 Billion | CN¥485.57 Million | ▲ +4.0 pp |
| 2023 | 57.3% | CN¥931.04 Million | CN¥1.62 Billion | CN¥693.52 Million | ▼ -3.9 pp |
| 2022 | 61.2% | CN¥1.14 Billion | CN¥1.86 Billion | CN¥720.32 Million | ▲ +3.2 pp |
| 2021 | 58.0% | CN¥1.46 Billion | CN¥2.51 Billion | CN¥1.06 Billion | ▲ +3.5 pp |
| 2020 | 54.5% | CN¥1.48 Billion | CN¥2.72 Billion | CN¥1.24 Billion | ▼ -14.2 pp |
| 2019 | 68.7% | CN¥1.31 Billion | CN¥1.91 Billion | CN¥599.60 Million | ▲ +2.0 pp |
| 2018 | 66.6% | CN¥1.38 Billion | CN¥2.07 Billion | CN¥689.97 Million | ▼ -12.0 pp |
| 2017 | 78.7% | CN¥1.30 Billion | CN¥1.65 Billion | CN¥352.40 Million | ▼ -8.3 pp |
| 2016 | 87.0% | CN¥1.17 Billion | CN¥1.34 Billion | CN¥174.57 Million | ▲ +3.7 pp |
| 2015 | 83.3% | CN¥1.12 Billion | CN¥1.34 Billion | CN¥223.98 Million | ▲ +16.5 pp |
| 2014 | 66.8% | CN¥374.13 Million | CN¥559.83 Million | CN¥185.70 Million | ▲ +6.5 pp |
| 2013 | 60.3% | CN¥351.02 Million | CN¥582.12 Million | CN¥231.09 Million | ▼ -4.4 pp |
| 2012 | 64.7% | CN¥236.22 Million | CN¥364.89 Million | CN¥128.67 Million | ▲ +12.1 pp |
| 2011 | 52.6% | CN¥128.55 Million | CN¥244.38 Million | CN¥115.83 Million | — |